Medication info

Celsita Tablet 100mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Light orange, round, double-convex film-coated tablets
Packaging
28 tablets (14 tablets/PTP x 2) - 14 tablets/PTP [28 tablets (14 tablets/PTP x 2)], 30 tablets (10 tablets/PTP x 3) - 10 tablets/PTP [30 tablets (10 tablets/PTP x 3)]
Approval status
Expired

MFDS item code 202005879 · Approved 2020.08.18

This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100mg once daily as monotherapy or combination therapy; the maximum daily dose is 100mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). Administer this medicine regardless of the timing of dialysis.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be administered alone and may be used in combination with metformin in cases where patients have never received diabetes medication or where blood sugar control is difficult with monotherapy. Additionally, this medication can be added when sufficient blood sugar control is not achieved with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin. In cases where blood sugar control is challenging even with concurrent therapies of multiple medications, this drug can also enhance the effect. It is utilized in various therapeutic situations to improve blood sugar control.

How to take

Adult dose

Administer 100mg once daily as monotherapy or combination therapy; the maximum daily dose is 100mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). Administer this medicine regardless of the timing of dialysis.

Precautions

This medication can cause rare but serious allergic reactions; therefore, if skin rash, difficulty breathing, swelling of the face or neck appear within three months after administration, use should be discontinued immediately, and a doctor consulted. It may cause inflammation of the pancreas (pancreatitis); if severe abdominal pain, vomiting, or fever occur, the medication should be discontinued immediately, and medical attention sought. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in those allergic to the drug or its components. In patients with impaired kidney function, the dose of this medication needs to be adjusted, and it should be taken only under the guidance of a physician. During treatment, symptoms of hypoglycemia may occur; hence, blood sugar levels should be monitored closely, especially when used in conjunction with insulin or sulfonylureas. While taking this medication, headaches, upper respiratory infections, nasopharyngitis, diarrhea, nausea, and other symptoms may occur; if symptoms persist or worsen, consultation with healthcare professionals is advised. If symptoms such as severe joint pain or blistering of the skin occur, the medication should be discontinued immediately and a specialist consulted. Pregnant or breastfeeding women are advised not to use this medication, and its safety and efficacy have not been established for children or adolescents under 18 years of age. In case of overdose, general symptomatic treatment should be conducted, with blood dialysis available to remove some of the drug if necessary, so patients should promptly seek medical attention in emergencies. This medication generally interacts little with other drugs, but it may change blood concentration levels for certain medications; therefore, healthcare providers should be informed of any drugs being taken. Elderly patients may experience decreased kidney function, so regular kidney function tests are recommended, which may require dose adjustments.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
Show 28 more
  • abdominal pain
  • nausea
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • vesiculobullous dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Light orange, round, double-convex film-coated tablets

Package unit

28 tablets (14 tablets/PTP x 2) - 14 tablets/PTP [28 tablets (14 tablets/PTP x 2)], 30 tablets (10 tablets/PTP x 3) - 10 tablets/PTP [30 tablets (10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.